Skip to content
Open in App
Bristol Myers Squibb logo

Bristol Myers Squibb

web2

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes,...

Symbol · BMYUS
Company profile

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

FDA accelerated approval of Zenbexus for multiple myeloma

KEY STEP

On August 13, 2026, the FDA granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab, hyaluronidase and dexamethasone for adults with multiple myeloma who had received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Zenbexus became the first FDA approved CELMoD medicine.

Roadmap reference
People

Company team

MR

Michael R. McMullen

Independent Director

Company leadership profile.

DW

Derica W. Rice

Independent Director

Company leadership profile.

CS

Christopher S. Boerner

CEO & Chairman

Company leadership profile.

PJ

Peter J. Arduini

Independent Director

Company leadership profile.

TR

Theodore Rapp Samuels

Lead Independent Director

Company leadership profile.

KH

Karen H. Vousden

Independent Director

Company leadership profile.

JA

Julia A. Haller

Independent Director

Company leadership profile.

PR

Phyllis R. Yale

Independent Director

Company leadership profile.

PA

Paula Ann Price

Independent Director

Company leadership profile.

MH

Manuel Hidalgo Medina

Independent Director

Company leadership profile.

DL

Deepak L. Bhatt

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Bristol Myers Squibb.

Orbitrum research

Experts evaluating Bristol Myers Squibb

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment